Overexpression of CD44 and its isoforms has been reported to be associated with poor prognosis in gliomas [15], breast cancer [16], pancreatic cancer [17], lung cancer [18], prostate cancer, and head and neck carcinoma [19]. This evidence concerns the gene CD44 and prostate carcinoma.